← Oncology Approval Tracker

FDA DECISION ·

Revtorpyk + fulvestrant

gedatolisib with fulvestrant, with or without palbociclib · Celcuity

FDA approvalNew therapyBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer without a detected PIK3CA mutation, after progression on or following at least one endocrine therapy line in the metastatic setting.

LAMPGEN ANALYSIS

Why it matters

The label creates a targeted option in a population defined by the absence of a detected PIK3CA mutation. VIKTORIA-1 studied two gedatolisib combinations against fulvestrant.

What research teams should watch

A negative molecular result needs a traceable test report and adequate specimen. Keep the two experimental regimens separate in safety and efficacy reporting.

Clinical operations takeaway

Give sites separate ways to record a documented negative result, an inadequate specimen, and a test that was never completed. Define who follows up and what the monitor checks for each status.

Plan biomarker screening and specimen workflows

PRIMARY RECORDS

Sources